Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 12/20 | 0.50 |
| ▸ | PPARG | P37231 | 11/20 | 0.50 |
| ▸ | PPARD | Q03181 | 9/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7108081 | 1.00 | SLC7A5 (0.51) | SLC7A5PPARAPPARGPPARDTAAR1 | |
| SCHEMBL5607289 | 1.00 | SLC7A5 (0.51) | SLC7A5PPARAPPARGPPARDTAAR1 | |
| SCHEMBL24328238 | 0.86 | SRR (0.62) | PPARAPPARGSRR | |
| SCHEMBL8023124 | 0.86 | SRR (0.62) | PPARAPPARGSRR | |
| SCHEMBL3963049 | 0.85 | PPARA (0.48) | SLC7A5PPARAPPARGPPARDTAAR1 | |
| SCHEMBL6732246 | 0.85 | PPARA (0.48) | SLC7A5PPARAPPARGPPARDTAAR1 | |
| SCHEMBL24328386 | 0.85 | PPARG (0.58) | PPARAPPARGPPARDSRR | |
| SCHEMBL3993110 | 0.83 | ESR1 (0.58) | SLC7A5TAAR1SLC6A2FOLH1ESR1 | |
| SCHEMBL13792677 | 0.83 | ESR1 (0.58) | SLC7A5TAAR1SLC6A2FOLH1ESR1 | |
| SCHEMBL4451311 | 0.82 | PPARA (0.56) | SLC7A5PPARAPPARGPPARDSRR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399297-A1 | Novel Glutamine Analogs | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230399297-A1 | Novel Glutamine Analogs | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-12-14 | — | — | US | disclosed |
| WO-2022078416-A1 | NOVEL GLUTAMINE ANALOGS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
| US-20030008361-A1 | Process for the preparation of substituted 3-phenyl-propanoic acid esters and substituted 3-phenyl-propanoic acids | EBDRUP SOREN (DK) | 2003-01-09 | — | — | US | disclosed |
| EP-1206565-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED 3-PHENYL-PROPANOIC ACID ESTERS AND SUBSTITUTED 3-PHENYL-PROPANOIC ACIDS | NOVO NORDISK A/S (DK) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001011073-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED 3-PHENYL-PROPANOIC ACID ESTERS AND SUBSTITUTED 3-PHENYL-PROPANOIC ACIDS | NOVO NORDISK A/S (DK) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399297-A1 | Novel Glutamine Analogs | GLUL, GATD3, GLS | SLC7A5 22/4885PPARA 1857/4885PPARG 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.